CN107595834A - Quercetin and curcumin drug combination are preparing the application in treating prostate cancer product - Google Patents
Quercetin and curcumin drug combination are preparing the application in treating prostate cancer product Download PDFInfo
- Publication number
- CN107595834A CN107595834A CN201711078962.9A CN201711078962A CN107595834A CN 107595834 A CN107595834 A CN 107595834A CN 201711078962 A CN201711078962 A CN 201711078962A CN 107595834 A CN107595834 A CN 107595834A
- Authority
- CN
- China
- Prior art keywords
- quercetin
- curcumin
- prostate cancer
- prostate
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses Quercetin and curcumin drug combination to prepare the application in treating prostate cancer product.The invention provides provide Quercetin and curcumin to prepare the application in treating human or animal's prostate cancer product.Present invention also offers Quercetin and curcumin to prepare the application in suppressing migration of prostate cancer cells and/or invasion and attack product.Quercetin and curcumin low dosage drug combination anti-prostate cancer, drug synergism, drug effect are obviously improved by the present invention, show lower drug toxicity, more preferably cancer resistant effect.
Description
Technical field
The invention belongs to biological technical field, more particularly to a kind of Quercetin and curcumin drug combination are before treatment is prepared
Application in row gland cancer product.
Background technology
In recent years, with the improvement of people ' s living standards, the change of dietary structure and the aging of population structure, China
Prostate-cancer incidence is in rising trend, and age of onset also rejuvenation increasingly, turns into the principal element for threatening men's health.
It is more than half during clinical definite to have broken through capsula prostatica or Bone tumour occurs because prostate cancer symptoms are hidden
And the chance of surgical radical treatment is lost, therefore non-operative treatment is in very important status in prostate cancer therapy.At present
Conventional Androgen deprivation therapy total effective rate is 70-80%, although curative effect is affirmed, treatment 18-24 is most of to suffer from after individual month
Person loses the sensitiveness to hormone therapy, is converted into castration-resistant prostate cancer (castration-resistant
Prostate cancer, CRPC), and the median survival interval of CRPC patient only has 1-2.Therefore, CRPC treatment is to compare at present
More intractable problem, and one of focus of research.During CRPC chemotherapeutic treatments, because single drug is present, drug effect is low, malicious secondary makees
With it is greatly etc. obvious the shortcomings that, and seek that new chemotherapeutics difficulty is high, therefore research is turned into the use in conjunction of existing medicine
Focus.Drug combination is the elementary tactics for treating malignant tumour, and its theoretical foundation is：While therapeutic effect is improved, reduce
The dosage and blood concentration of each medicine, reduce each potential toxic side effect and occur.Research has shown that Quercetin and curcumin
Promote apoptosis of tumor cells by more signal paths, be the new anticancer drug of two kinds of wide potential applicability in clinical practices.
Quercetin is a kind of flavonoids of plant origin, is distributed widely in veterinary antibiotics, dry fruit, beverage and Chinese herbal medicine,
With multiple biological activities such as anticancer, anti-oxidant, anti-inflammatory, expansion blood vessel, antiallergic actions.Ground from National Cancer in 1971
Study carefully after finding Quercetin to the inhibitory action of leukaemia first, domestic and foreign scholars have been carried out extensively and profoundly to its antitumaous effect
Research.First, Quercetin can play cancer chemoprevention by number of ways and act on.For example, Quercetin can suppress heterocyclic amine, Huang
The precarcinogen such as aspergillin are converted into carcinogenic substance；Strengthen the activity of glutathione-S-transferase, superoxide dismutase etc., promote
Enter metabolic detoxification and discharge of the carcinogen in liver；Effectively capture and scavenging activated oxygen, prevent or mitigate oxygen radical to lure
Send out possibility of cell carcinogenesis etc..Except being acted on cancer chemoprevention, Quercetin can produce CDCC to cancer cell.Research
Confirm that Quercetin can suppress the growth of the kinds of tumor cells such as prostate cancer, colon cancer, breast cancer, liver cancer.Made based on its anticancer
With Quercetin has been used to treat advanced prostate cancer in the U.S. as non-prescribed medicine.
Curcumin is a kind of xanthein for extracting to obtain from the rhizome of zingiberaceous plant turmeric etc..For acid polyphenols class thing
Matter, main chain are unsaturated aliphatic and aromatic group.Curcumin is used in food industry as a kind of natural pigment very early.
It is stable to reducing agent, strong coloring force, not fugitive color, but sensitive to light, heat and iron ion.Be mainly used in can, intestines based article,
The dyeing of sauce spiced and stewed food, also serves as acid-base indicator.Curcumin also has important economic value and extensive pharmacological action, such as drops
Blood fat, anti-oxidant, anti-inflammatory, antiatherosclerosis etc..In addition, anticancer is one of primary pharmacological activity of curcumin, it presses down
The effect of tumour processed is confirmed that its specific anticancer mechanism turns into recent research focus repeatedly in many zooperies.
There is presently no the relevant report on Quercetin and curcumin use in conjunction.
The content of the invention
A purpose of the invention is to provide the purposes of Quercetin and curcumin.
The invention provides Quercetin and curcumin to prepare the application in treating human or animal's prostate cancer product.
Present invention also offers Quercetin and curcumin in suppression migration of prostate cancer cells and/or invasion and attack product is prepared
Application.
In above-mentioned application, the suppression migration of prostate cancer cells is suppression prostate gland cancer cell lateral transfer and/or indulges
To migration.
The molar concentration rate of the Quercetin and the curcumin is 1:1；
In above-mentioned application, the prostate gland cancer cell derives from human or animal；
Or the prostate gland cancer cell is PC-3 cells or LNCaP cells.
Another object of the present invention is to provide a kind of product.
Product provided by the invention, its active component are Quercetin and curcumin.
The molar concentration of the Quercetin and the curcumin is 1:1；
The said goods have following 1) -3) at least one of function：
1) human or animal's prostate cancer is treated；
2) migration of prostate cancer cells is suppressed；
3) prostate gland cancer cell invasion and attack are suppressed.
In the said goods, the prostate gland cancer cell is PC-3 cells or LNCaP cells.
3rd purpose of the invention is to provide a kind of method for suppressing migration of prostate cancer cells and/or invasion and attack.
Method provided by the invention, comprises the following steps：Quercetin and curcumin addition are being contained into prostate gland cancer cell
Cultivating system in, obtain medicine effect system, culture, realize and suppress migration of prostate cancer cells and/or invasion and attack.
In the above method, the molar concentration rate of the Quercetin and the curcumin is 1:1；
Or, concentration of the Quercetin in the medicine effect system is 30 μm of ol/L；
Concentration of the curcumin in the medicine effect system is 30 μm of ol/L.
The present invention controls Quercetin and curcumin low dosage drug combination anti-prostate cancer with Quercetin, curcumin list medicine
Treatment is compared, and drug synergism, drug effect is obviously improved, and shows lower drug toxicity, more preferably cancer resistant effect.
Brief description of the drawings
Fig. 1 is scratch experiment experimental result.
Fig. 2 is scratch experiment analysis of experimental results.
Fig. 3 is that Transwell migrates experimental result.
Fig. 4 is that Transwell migrates analysis of experimental results.
Fig. 5 is Transwell Matrigel results.
Fig. 6 is Transwell Matrigel interpretations of result.
Embodiment
Experimental method used in following embodiments is conventional method unless otherwise specified.
Material used, reagent etc., unless otherwise specified, are commercially obtained in following embodiments.
Embodiment 1, Quercetin and curcumin combination are to prostate gland cancer cell medication
First, Quercetin and curcumin combination are to prostate gland cancer cell medication
Following prostate gland cancer cell is PC-3 cells or LNCaP cells：
PC-3 cells (hereinafter also referred to PC3 cells), Shanghai Inst. of Life Science, CAS cell resource center,
Catalog number (Cat.No.) TCHu158；
LNCaP cells, Shanghai Inst. of Life Science, CAS cell resource center, catalog number (Cat.No.) TCHu173.
Prostate gland cancer cell is divided into following several groups of difference medications：
Quercetin treatment group：Prostate gland cancer cell cultivates 24h in the culture medium containing Quercetin, and it is independent to obtain Quercetin
Prostate gland cancer cell after treatment.
Culture medium containing Quercetin is that Quercetin adds 1640 culture mediums, obtains the culture medium containing Quercetin, and Mongolian oak
The concentration of Pi Su in the medium is 30 μm of ol/L.
Curcumin treatment group：Prostate gland cancer cell cultivates 24h in the culture medium containing curcumin, and it is independent to obtain curcumin
Prostate gland cancer cell after treatment.
Culture medium containing curcumin is that Quercetin adds 1640 culture mediums, obtains the culture medium containing curcumin, and ginger
The concentration of flavine in the medium is 30 μm of ol/L.
Quercetin and curcumin therapeutic alliance group：Prostate gland cancer cell cultivates 24h in the culture medium containing curcumin, obtains
Prostate gland cancer cell after to Quercetin and curcumin therapeutic alliance.
Culture medium containing Quercetin and curcumin is that Quercetin and curcumin add 1640 culture mediums, is obtained containing quercitrin
The culture medium of element and curcumin, and the concentration of Quercetin in the medium is 30 μm of ol/L, the concentration of curcumin in the medium
For 30 μm of ol/L.
Control group：Prostate gland cancer cell cultivates 24h in 1640 culture mediums, obtains cellular control unit.
2nd, scratch experiment detects
1st, first marker pens are used behind, to be compared with ruler in 6 orifice plates, equably draw horizontal line, 1cm mono- is arrived per every about 0.5
Road, cross via.Per hole at least across 5 lines.
2nd, about 5X10 is separately added into hole5Cell and cellular control unit after each group is treated in individual above-mentioned one, are paved with overnight.
3rd, ruler is compared with pipette tips within second day, as far as possible perpendicular to the horizontal line cut of behind, pipette tips are vertical, not tilt.
4th, wash cell 3 times with PBS, remove the cell under drawing, add serum free medium.
5th, 37 DEG C, 5%CO are put into2Incubator culture.Sampled, take pictures by 24 hours.
As a result such as Fig. 1, (left side is before processing wherein in PC3 cells or LNCaP cell each groups, and the right is each group of processing
Afterwards) and Fig. 2, compared with Quercetin treatment group and curcumin treatment group act on, before Quercetin and curcumin therapeutic alliance are to suppression
Row adenocarcinoma cell lateral transfer effect is remarkably reinforced.
3rd, Transwell migrations and Matrigel
Microscope capable of taking pictures, Transwell cells, 8 μm of aperture, the hole of Tissue Culture Plate 24 of Transwell migration experiments
Plate.Tissue Culture Plate should match with the Transwell cells of purchase, the Matrigel of BD companies, serum-free DMEM, and (1%
Hyclone) DMEM and 1640 culture mediums, DMEM complete mediums, 1640 complete mediums (can also be added to 20% serum), nothing
Bacterium PBS, cotton swab, pancreatin, 4% paraformaldehyde fixer, crystal violet dye liquor (0.1% (g/ml) PBS crystal violets)
1st, matrigel bed board
With the Matrigel 1 of BD companies：8 dilutions, the upper chamber face of coating Transwell cells bottom film, put 37 DEG C
30min makes Matrigel aggregate into gel.Use preceding progress basilar memebrane aquation.
2nd, cell suspension is prepared
1) above-mentioned each treatment group is handled to 24h cell, removes serum starvation 12h.2) vitellophag：Serum famine is removed by above-mentioned
Cell after starving adds pancreatin digestion 3min, terminates centrifugation after digesting and discards nutrient solution, is washed 2 times with PBS, with 1640 containing BSA
Culture medium is resuspended, adjustment cell density to 5 × 105/ ml, obtains cell suspension.
3rd, inoculating cell
The above-mentioned μ l of cell suspension 100 are added into Transwell cells, cellar culture 24h.
Room typically adds 600 culture mediums of the μ l containing 20%FBS under orifice plate,
Direct counting method, " adherent " cell count, after so-called here " adherent " refers to that cell passes through film, it can be attached to
The lower room side of film is gone without dropping to inside lower room, by that to cell dyeing, can count cell under mirror.
Transwell cells are taken out, nutrient solution in hole is discarded, is washed 2 times with the PBS without calcium, methanol fixes 30 minutes, will be small
Room suitably air-dries.0.1% violet staining 20min, the non-migrating cell in upper strata is dabbed off with cotton swab, is washed 3 times with PBS.400 times
Cell, numeration are observed in five visuals field immediately under microscope.
As a result as seen in figures 3-6, it can be seen that compared with Quercetin treatment group and curcumin treatment group act on, Quercetin
It is remarkably reinforced with curcumin therapeutic alliance group to suppressing the effect of prostate gland cancer cell vertical migration and invasion and attack effect.
Claims (9)
1. Quercetin and curcumin are preparing the application in treating human or animal's prostate cancer product.
2. Quercetin and curcumin are preparing the application in suppressing migration of prostate cancer cells and/or invasion and attack product.
3. application according to claim 2, it is characterised in that：The suppression migration of prostate cancer cells is suppression prostate
Cancer cell lateral transfer and/or vertical migration.
4. according to any described application in claim 1-3, it is characterised in that：The prostate gland cancer cell is from people or dynamic
Thing；
Or the prostate gland cancer cell is PC-3 cells or LNCaP cells.
5. a kind of product, its active component is Quercetin and curcumin.
6. product according to claim 5, it is characterised in that：
The molar concentration rate of the Quercetin and the curcumin is 1:1；
Or, the product has following 1) -3) at least one of function：
1) human or animal's prostate cancer is treated；
2) migration of prostate cancer cells is suppressed；
3) prostate gland cancer cell invasion and attack are suppressed.
7. the product according to claim 5 or 6, it is characterised in that：The prostate gland cancer cell is PC-3 cells or LNCaP
Cell.
8. a kind of method for suppressing migration of prostate cancer cells and/or invasion and attack, comprises the following steps：Quercetin and curcumin are added
It is added in the cultivating system containing prostate gland cancer cell, obtains medicine effect system, culture, realize that suppressing prostate gland cancer cell moves
Move and/or attack.
9. according to the method for claim 8, it is characterised in that：The molar concentration rate of the Quercetin and the curcumin is
1:1；
Or concentration of the Quercetin in the medicine effect system is 30 μm of ol/L；
Concentration of the curcumin in the medicine effect system is 30 μm of ol/L.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711078962.9A CN107595834A (en) | 2017-11-06 | 2017-11-06 | Quercetin and curcumin drug combination are preparing the application in treating prostate cancer product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711078962.9A CN107595834A (en) | 2017-11-06 | 2017-11-06 | Quercetin and curcumin drug combination are preparing the application in treating prostate cancer product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107595834A true CN107595834A (en) | 2018-01-19 |
Family
ID=61085673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711078962.9A Pending CN107595834A (en) | 2017-11-06 | 2017-11-06 | Quercetin and curcumin drug combination are preparing the application in treating prostate cancer product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107595834A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112205628A (en) * | 2020-09-18 | 2021-01-12 | 广州大学 | Composite condensate with double embedding functions and preparation method and application thereof |
| CN113144134A (en) * | 2020-12-28 | 2021-07-23 | 完美（中国）有限公司 | Pharmaceutical composition for inhibiting prostate cancer and application thereof |
| CN114848617A (en) * | 2022-05-06 | 2022-08-05 | 天津中医药大学第一附属医院 | Application of traditional Chinese medicine monomer curcumin in preparation of tumor treatment medicines |
-
2017
- 2017-11-06 CN CN201711078962.9A patent/CN107595834A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| KALIMUTHU SENTHILKUMAR ET AL.: "Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3)", 《CELL BIOCHEM FUNCT》 * |
| VIKAS SHARMA ET AL.: "Sensitization of androgen refractory prostate cancer cells to antiandrogens through re-expression of epigenetically repressed androgen receptor e Synergistic action of quercetin and curcumin", 《MOLECULAR AND CELLULAR ENDOCRINOLOGY》 * |
| 齐瑞芳等: "姜黄素对前列腺癌PC3细胞迁移的抑制作用及对MMP2体内表达的影响", 《中国中医基础医学杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112205628A (en) * | 2020-09-18 | 2021-01-12 | 广州大学 | Composite condensate with double embedding functions and preparation method and application thereof |
| CN113144134A (en) * | 2020-12-28 | 2021-07-23 | 完美（中国）有限公司 | Pharmaceutical composition for inhibiting prostate cancer and application thereof |
| CN114848617A (en) * | 2022-05-06 | 2022-08-05 | 天津中医药大学第一附属医院 | Application of traditional Chinese medicine monomer curcumin in preparation of tumor treatment medicines |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Han et al. | Rosmarinic acid activates AMPK to inhibit metastasis of colorectal cancer | |
| Pan et al. | Kaempferol inhibits the migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes by blocking activation of the MAPK pathway | |
| Kee et al. | Inhibitory effect of quercetin on colorectal lung metastasis through inducing apoptosis, and suppression of metastatic ability | |
| CN107595834A (en) | Quercetin and curcumin drug combination are preparing the application in treating prostate cancer product | |
| Shen et al. | Neuron regeneration and proliferation effects of danshen and tanshinone IIA | |
| CN109498651A (en) | A kind of preparation method, medicament and the application of antitumor microparticle | |
| Kim et al. | Isoliquiritin apioside suppresses in vitro invasiveness and angiogenesis of cancer cells and endothelial cells | |
| Kim et al. | Rhaponticin decreases the metastatic and angiogenic abilities of cancer cells via suppression of the HIF‑1α pathway | |
| Suziana Zaila et al. | Antiproliferative effect of Lignosus rhinocerotis, the Tiger Milk Mushroom on HCT 116 human colorectal cancer cells | |
| Im et al. | Ethanol extract of baked Gardeniae Fructus exhibits in vitro and in vivo anti-metastatic and anti-angiogenic activities in malignant cancer cells: Role of suppression of the NF-κB and HIF-1α pathways | |
| Shen et al. | Ethanol extract of root of Prunus persica inhibited the growth of liver cancer cell HepG2 by inducing cell cycle arrest and migration suppression | |
| Nurhidayati et al. | Antiangiogenesis Activity of Awar-Awar Leaf Extract (Ficus Septica Burm. F.) In Chorioallantoic Membrane Assay. | |
| Habtemariam et al. | Antioxidant, anti-alpha-glucosidase and pancreatic beta-cell protective effects of methanolic extract of Ensete superbum Cheesm seeds | |
| Mesmar et al. | Ethanolic extract of Origanum syriacum L. leaves exhibits potent anti-breast cancer potential and robust antioxidant properties | |
| CN102198195A (en) | Antioxidative medicinal composition | |
| Rocio Soledad et al. | Yerba Mate modulates tumor cells functions involved in metastasis in breast cancer models | |
| CN101104845A (en) | Use of protocatechuic acid in accelerating nerve stem cell multiplication in vitro and inducement differentiation | |
| CN111658655A (en) | Application of cucurbitacin B in preparation of iron death inducer and anti-nasopharyngeal carcinoma drug | |
| US9675563B2 (en) | Method for adjunctive treatment of cancer metastasis by using lycogen | |
| CN104815014A (en) | Application of polygonum cuspidatum in preparation for medicine for preventing and treating ionization radiation-induced intestinal injuries | |
| CN106955289A (en) | Punicalagins are preparing the application in treating or preventing the medicine of inflammation caused by influenza infection | |
| Zhang et al. | Mechanism of Bazi Bushen capsule in delaying the senescence of mesenchymal stem cells based on network pharmacology and experimental validation | |
| Hussain et al. | Cytotoxicity evaluation and characterization of chloroform extract of leaf of Piper sarmentosum possessing antiangiogenic activity | |
| Ling et al. | Baicalein inhibits angiogenesis induced by lipopolysaccharide through TRAF6 mediated toll-like receptor 4 pathway | |
| Lee et al. | Anti-cancer Activities of Ginseng Extract Fermented with Phettinus linteus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180119 |
|
| RJ01 | Rejection of invention patent application after publication |